EyePoint

EYPT · NASDAQ

$0.4052−$0.0348 (−7.91%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $0.44

Latest news

Press releaseOct 20, 10:09 AM ETPRNewswire
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
NewsOct 19, 9:04 PM ETShivdeep Dhaliwal
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
Press releaseOct 19, 5:58 PM ETPRNewswire
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
NewsOct 19, 2:57 PM ETAvi Kapoor
Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
NewsOct 19, 1:16 PM ETVandana Singh
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
NewsOct 19, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsOct 19, 9:45 AM ETAvi Kapoor
Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
Press releaseOct 19, 7:15 AM ETGlobe Newswire
EyePoint Announces Strategic Prioritization
Press releaseOct 19, 7:00 AM ETGlobe Newswire
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
Press releaseSep 24, 5:34 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Press releaseSep 22, 7:21 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NewsSep 18, 8:01 AM ETAvi Kapoor
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Press releaseSep 10, 12:10 PM ETGlobe Newswire
EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Press releaseSep 6, 11:00 AM ETPRNewswire
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Press releaseSep 4, 9:51 AM ETGlobe Newswire
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm
Press releaseSep 2, 8:00 PM ETGlobe Newswire
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals
Press releaseSep 2, 3:04 PM ETGlobe Newswire
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
Press releaseSep 1, 8:00 PM ETBusiness Wire
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Press releaseSep 1, 6:27 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Press releaseAug 28, 7:10 PM ETPRNewswire
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
Press releaseAug 28, 2:11 PM ETBusiness Wire
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
Press releaseAug 27, 4:22 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Press releaseAug 27, 8:25 AM ETGlobe Newswire
Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
Press releaseAug 26, 8:00 PM ETGlobe Newswire
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Press releaseAug 26, 4:51 PM ETBusiness Wire
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
Press releaseAug 26, 10:11 AM ETPRNewswire
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
Press releaseAug 25, 6:19 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Press releaseAug 21, 10:09 AM ETBusiness Wire
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
Press releaseAug 20, 1:03 PM ETPRNewswire
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
NewsAug 17, 9:39 PM ETShivdeep Dhaliwal
Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today
NewsAug 17, 1:48 PM ETVandana Singh
Why Is Ocular Therapeutix Stock Gaining Monday?
NewsAug 17, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsAug 17, 12:03 PM ETAvi Kapoor
Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August
NewsAug 17, 10:40 AM ETVandana Singh
EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study
NewsAug 17, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseAug 17, 7:00 AM ETGlobe Newswire
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
Press releaseAug 5, 7:00 AM ETGlobe Newswire
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Press releaseJul 30, 7:00 AM ETGlobe Newswire
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
Press releaseJul 13, 7:00 AM ETGlobe Newswire
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseSep 4, 7:00 AM ETGlobe Newswire
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
Press releaseAug 7, 7:00 AM ETGlobe Newswire
EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today

EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)

Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October

EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus

12 Health Care Stocks Moving In Monday's Intraday Session

Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views

EyePoint Announces Strategic Prioritization

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm

EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals

EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm

EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm

EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today

Why Is Ocular Therapeutix Stock Gaining Monday?

12 Health Care Stocks Moving In Monday's Intraday Session

Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August

EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study

12 Health Care Stocks Moving In Monday's Pre-Market Session

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

Earnings Scheduled For May 6, 2026

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments